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study
Goto Gangkak*, Ram Dayal Teli, Sher Singh Yadav, Vinay Tomar, Shivam Priyadarshi and Satinder Pal Aggarwal
Abstract 
A prospective double-blinded placebo controlled randomized study was conducted in our institute to compare 
the efficacy of oral Silodosin, an alpha 1 selective antagonist and Diclofenac in relieving pain after stent removal. All 
patients with unilateral stent placement following renal and ureteric stone endoscopic surgery were randomized into 
four groups: group A (Placebo), group B (Diclofenac), group C (Silodosin) and group D (combination of Diclofenac and 
Silodosin). Visual analogue score (VAS score) and other relevant parameters were assessed during OPD visit. Patients 
were handed over randomized drug envelope and asked to take the medications one hour before the stent removal. 
Patients were contacted 24 h after stent removal and relevant parameters were recorded. The mean VAS scores were 
significantly decreased in Diclofenac (2.9), Silodosin (3.08) and combination group (2.85) when compared to pla-
cebo (4.20) (p < 0.001). However there was no statistically significant difference in VAS scores between the treatment 
groups, i.e., group B, C and D (p > 0.5). Analgesics requirement and severe pain rates were not significantly reduced 
(p = 0.07, 0.35) in the three treatment groups when compared to placebo. Thus Silodosin and Diclofenac, both are 
effective in preventing pain after stent removal.
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Background
Ureteral stents have become an indispensable tool for the 
urologist but they are often associated with significant 
morbidity. A significant number of patients often report 
pain and urinary symptoms with indwelling stents (Joshi 
et  al. 2003). Extensive studies have been done to assess 
stent-related discomfort but these studies have primar-
ily assessed the stent-related pain, while stent was in situ 
(Dellis et  al. 2010; Gupta et  al. 2010; Beddingfield et  al. 
2009; Rane et al. 2001; Deliveliotis et al. 2006; Damiano 
et  al. 2008). But it is a common observation that many 
patients complain of renal colic type of pain after stent 
removal, which often requires admission and additional 
analgesics. There has been only one previous study, 
describing this phenomenon of pain after stent removal 
by Tadros et  al. (2012) and they concluded that signifi-
cant number of patients had pain after stent removal and 
Rofecoxib, a selective cyclooxygenase (COX) inhibitor 
was effective in reducing pain after stent removal. They 
ascribed the pain relief to the analgesic, anti-inflam-
matory as well as smooth muscle relaxing properties 
of the non-steroidal anti-inflammatory drug (NSAID). 
Diclofenac, a long acting NSAID with a quick onset of 
action has been quite effective in treatment of renal colic 
(Davies and Anderson 1997; Tankó and Tamás 1995–
1996; Hurault and Ryckelynck 1989). Alpha blockers 
have been found to be quite effective in relieving stent-
related pain (Deliveliotis et al. 2006; Damiano et al. 2008). 
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Silodosin is a long acting alpha 1 selective antagonist 
with rapid onset of action (Michel 2010). But no study 
is available to assess their effectiveness in relieving pain 
after stent removal. So, we conducted this study to com-
pare the effectiveness of oral Silodosin, Diclofenac and 
their combination in reducing pain after stent removal.
Methods
The prospective, randomized, double-blinded, placebo-
controlled study was conducted in our department after 
taking clearance from our institute’s ethics committee. All 
patients above 17  years and below 55  years undergoing 
unilateral ureteral stenting following renal and ureteric 
stone surgery were included. In all the patients, 5 Fr dou-
ble J (DJ) polyurethane ureteral stent was used. DJ stent 
was kept for a period of 3 weeks before removal. A total 
of 272 patients were enrolled in the study from January 
2014 to March 2015. Patients with history of peptic ulcer 
disease, liver impairment, chronic renal failure, coronary 
artery disease, bleeding diathesis, asthma, urinary tract 
infections (UTI), chronic painful conditions like arthri-
tis, pregnancy, allergy to medications, significant lower 
urinary tract symptoms (LUTS) and use of alpha block-
ers and residual calculus were excluded. Patients with 
complications during stent removal like hematuria and 
mucosal injury were also excluded. Out of 272 patients, 
240 patients were included in our study after exclud-
ing 32 patients not fulfilling the inclusion criteria. The 
patients were then randomized into four groups: group A 
(Placebo), group B (Diclofenac), group C (Silodosin) and 
group D (combination of Diclofenac and Silodosin) using 
a computer generated model. 60 patients were taken in 
each group. A vitamin tablet containing folic acid was 
used as placebo. 50  mg Diclofenac sodium oral tablet 
and 8 mg Silodosin oral tablet were used in the treatment 
groups. All medications were placed in numbered enve-
lope as per the computer generated model. All patients 
and investigators were blinded to the medicine iden-
tity and randomistaion design till the end of the study. 
Patients were handed over the next numbered envelope 
on their OPD visit and Visual analogue score (VAS score) 
was also recorded at the same time. Visual analogue score 
was taken on a scale from zero to ten, zero meaning no 
pain to 10 meaning excruciating pain. Patients were 
asked to take the medications 1 h before the procedure. 
All patients received a single dose of levofloxacin 500 mg 
before stent removal as per our department protocol. The 
surgeon removing the stent was also blinded about the 
grouping. Stent removal was performed under local anes-
thesia using 2  % xylocaine jelly under vision with 8/9.8 
ureteroscope. All patients were contacted after 24 h and 
VAS score, additional medications requirement and site 
of pain and any other relevant parameters were recorded. 
Additional analgesics dose was measured in mgs of 
i.v morphine equivalents. Patients with severe pain or 
patient willing for admission were readmitted.
Statistics
Chi square test was used for sex-data analysis. One way 
Anova, Mann–whitney test and Kruskal–Wallis test were 
used for analyzing all the other datas. Our sample size 
calculation of 50 patients per study arm was powered to 
detect a 20 % decrease in the VAS score with a 95 % con-
fidence level.
Results
Out of 240 patients included in the study, 22 patients 
were further excluded from final analysis (Fig.  1). 
10 patients did not report back to us, 3 patients had 
migrated stent, 3 patients had complicated procedure, 
2 patients had significant hematuria following stent 
removal and 4 patients had febrile UTI requiring intra-
venous (i.v) antibiotics and admission. So a total of 218 
patients were taken up for analysis.
All the four groups were analysed for baseline char-
acteristics for comparability (Table  1). The results were 
comparable for all the assessed baseline parameters. The 
age of patients ranged from 19 to 55 years in our study 
and all groups were comparable for age (p = 0.17). Num-
ber of male and female patients were not equally distrib-
uted in all the four groups but there was no statistically 
significant difference (p  =  0.38). Diclofenac group had 
more number of male patients and less female patients, 
but it was statistically insignificant (p = 0.23). Most com-
mon diagnosis was ureteric stone (89  %). There was no 
difference in diagnosis among various groups (p = 0.45). 
One hundred and nineteen patients had stents on the 
right side and 99 patients had on the left side. There was 
no difference between the side of stenting among all 
groups (p = 0.90). Duration of stenting also was found to 
be statistically insignificant among all groups (p = 0.08). 
The mean duration of stent insertion was 23.5, 25.4, 21.7 
and 22.5  days in group A, group B, group C and group 
D, respectively. The mean pre-stent removal VAS score 
was 3.4, 3.2, 3.7 and 3.1 in group A, group B, group C and 
group D, respectively (p = 0.98).
All the four groups were analysed for post stent 
removal VAS score. The mean post stent removal VAS 
score measured at 24  h were 4.2 in placebo group, 2.9 
in Diclofenac group, 3.08 in Silodosin group and 2.85 
in the combination group (Fig.  2a, b). The post stent 
removal VAS score was significantly lower in Diclofenac 
group as compared to Placebo group (p  <  0.001). Simi-
lar results were obtained for Silodosin vs Placebo group 
(p  <  0.001). But there was no statistical difference 
between the Diclofenac and Silodosin group (p = 0.30). 
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The combination group (group D) had significant reduc-
tion in VAS score as compared to placebo (p < 0.001) but 
there was no significant difference when compared to Sil-
odosin (p = 0.30) and Diclofenac (0.95). 9 patients (17 %) 
in Placebo group reported to have severe pain, defined as 
VAS score >5, but the incidence was not statistically sig-
nificant when compared to all the three treatment groups 
(p = 0.08).
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( n=60)
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B (DICLOFENAC) 
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Fig. 1 The flowchart showing the study design
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Loin pain was the most common presentation after 
stent removal, however it occurred with similar inci-
dence in all three groups (p  =  0.32). Only 5  % of the 
patients experienced suprapubic pain in Silodosin group 
but it was not statistically significant as compared to all 
other groups (p =  0.15). The mean additional analgesic 
requirement was least in combination group (3 mg), but 
did not achieve statistical significance (p  =  0.70). The 
readmission rate also was similar in all four groups. No 
treatment-related significant side effects were seen in any 
of the groups.
Discussion
Ureteral stents are associated with significant pain and 
discomfort (Joshi et  al. 2002, 2003; Pollard and Mac-
farlane 1988). Joshi et  al. reported that 80 % of patients 
experienced stent-related pain (Joshi et al. 2003). Numer-
ous studies have been done to reduce stent-related pain 
and discomfort using drugs like alpha blockers, anticho-
linergics, phosphodiesterase inhibitors etc., new stent 
designs, stent materials and stent dimensions (Dellis 
et  al. 2010; Gupta et  al. 2010; Beddingfield et  al. 2009; 
Rane et  al. 2001; Deliveliotis et  al. 2006; Damiano et  al. 
2008). Most of the available literature focuses on the 
stent-related morbidity when stent was in  situ. But to 
any urologist, it is not unusual to have patients com-
plaining of renal colic like pain after stent removal which 
Table 1 Demographics and outcome of the patients
Variables Placebo Diclofenac Silodosin Silodosin + Diclofenac p value
Group A Group B Group C Group D
Mean ± SD age in years 34.7 ± 10.8 36.4 ± 13.5 32.3 ± 9.9 40.2 ± 9.8 0.17
Sex M/F 40/13 45/11 36/15 42/16 0.38
Diagnosis
 Ureteric stone 47 51 48 49 0.26
 Renal stone 6 5 3 9
Side
 Left 28 18 21 31 0.90
 Right 25 38 30 27
Mean ± SD duration of stenting in days 23.5 ± 3.7 25.4 ± 2.6 21.7 ± 2.3 22.5 ± 2.8 0.06
A–C (0.01)
Mean ± SD pre-stent removal VAS score 3.4 ± 0.9 3.5 ± 0.9 3.7 ± 1.0 3.2 ± 0.8 0.98
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Mean ± SD additional analgesics requirement in mg  
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Fig. 2 a The mean post stent removal VAS score in all the groups. b 
The change in VAS score between various groups
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often require additional analgesics and admission due 
to the severity of pain. Pain during stent removal prob-
ably occurs due to activation of nociceptors, the friction 
between stent and mucosa leading to ureteral smooth 
muscle irritability, trigonal irritation as well as pressure-
induced changes in pelvi-calyceal system. However, this 
phenomenon of pain after stent removal has remained 
neglected and unreported. Tadros et al. (2012) first stud-
ied the efficacy of Rofecoxib in relieving pain after stent 
removal in a placebo-controlled randomized study and 
found that a significant number of patients complained 
of severe pain after stent removal in the placebo group 
and none in the NSAID group (8). NSAIDs are consid-
ered the gold standard drugs for renal colic (Davies and 
Anderson 1997; Tankó and Tamás 1995–1996; Hurault 
and Ryckelynck 1989). Numerous animal studies as well 
human studies have shown that NSAIDs cause significant 
decrease in ureteral contractility as well as decrease in 
renal blood flow (Chaignat et  al. 2008; Perlmutter et  al. 
1993). Chaignat et al. (2008) have also demonstrated the 
presence of COX-1 and COX-2 receptors in human ure-
ters. Nakada et  al. (2000) reported that selective COX 
inhibitors and non-selective COX inhibitor led to sig-
nificant reduction in ureteral contractility in both por-
cine and human ureteral tissues. Also, alpha blockers 
have been found to be effective in relieving stent-related 
pain (Deliveliotis et al. 2006; Damiano et al. 2008). Alpha 
1 receptors have been found to be widely distributed in 
human ureter and bladder (Michel and Vrydag 2006; Itoh 
et al. 2007). Decrease in ureteral contractions as well as 
trigonal irritation are the likely mechanisms for the relief 
of stent-related pain with alpha blockers. Beddingfield 
et al. (2009) also reported a significant reduction in stent-
related pain as well as reduction in narcotic dose with the 
use of Alfuzosin.
In our study, oral Diclofenac, which has a rapid onset 
of action and long t½ in inflamed tissues (Davies and 
Anderson 1997; Tankó and Tamás 1995–1996; Hurault 
and Ryckelynck 1989), significantly reduced pain after 
stent removal as compared to placebo (p ≤ 0.001). There 
was also less incidence of severe pain and additional 
analgesics requirement when compared to placebo but it 
was not statistically significant (p = 0.35, 0.56). Thus, the 
pain relief observed with Diclofenac was probably due to 
its inhibitory actions on ureteral contractility and renal 
blood flow as well as its analgesic and anti-inflammatory 
properties. However, the inflammation and edema may 
takes days to subside. So, this action probably plays a less 
significant role in the described setting.
In our study, there was significant reduction in pain in 
the Silodosin group as compared to placebo (p ≤ 0.001). 
Patients had less severe pain in Silodosin group as 
compared to placebo group but it was not statistically 
significant (p  =  0.9). The mechanism of pain relief 
described in previous studies probably explains the pain 
relief seen with Silodosin in our study. The ureteral dila-
tory effect as well the decrease in ureteral and detru-
sor contractility by Silodosin are the likely mechanisms 
responsible for the pain reduction observed with Silodo-
sin. There was also less incidence of suprapubic pain in 
Silodosin group but the results were not statistically sig-
nificant (p = 0.15). This is probably related to Silodosin’s 
similar effect on lower urinary tract symptoms (LUTS) in 
BPH patients.
There was no difference in pain relief between both 
Silodosin and Diclofenac groups (p  =  0.48). There 
was higher pain reduction seen with combination of 
Diclofenac and Silodosin but it did not attain statistical 
significance (p =  0.9, 0.40). Possible explanation is that 
there is probably certain overlap of different mechanisms 
of pain reduction involved between both the drugs. how-
ever The incidence of severe pain (VAS  >  5) was also 
least in the combination group (3.4  %) when compared 
to all the other groups, but contrary to previous study, it 
was not statistically significant (p =  0.10). Tadros et  al. 
demonstrated significant reduction in analgesic require-
ment with NSAIDs. However, the additional analgesics 
requirement in our study was least in combination arm 
but it was not statistically significant (p = 0.70). However 
we did not keep any objective criteria for use of addi-
tional analgesia and analgesics are used on demand basis. 
So it is likely that these factors might have influenced on 
our result.
Use of both Diclofenac and Silodosin and their com-
bination did not result in any significant side effects in 
our study. Like other non-steroidal anti-inflammatory 
drugs, gastrointestinal side effects are the most com-
monly reported adverse effects of Diclofenac and seen 
in about 10  % of patients. These side effects have been 
found to be dose related (Lehtola and Sipponen 1977). 
These side effects with Diclofenac dose of 75–125  mg 
have been much lower than with aspirin 3–5 g (Brogden 
et al. 1980). Silodosin is comparatively a much safer drug 
with excellent side effect profile due to its unmatched 
uro-selectivity (Van Dijk et al. 2006). Silodosin has been 
reported to be frequently associated with abnormal ejac-
ulation however, its clinical relevance remains unclear, 
as subjects rarely discontinue treatment due to this side 
effect (Marks et al. 2009). Moreover, with the single dos-
ing of both the drugs, these side effects are unlikely to be 
of clinical significance, which is supported by our study 
results.
Thus our study supports the use of Diclofenac and 
Silodosin in reducing the pain after stent removal. How-
ever, ours is a preliminary study and further research 
is required in this field to better understand the 
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phenomenon of pain after stent removal and the mecha-
nisms of pain reduction involved.
However, there are certain shortcomings to our study. 
We took the pain score only after 24 h. If we could have 
taken more frequent pain scores before and even after 
24 h, we could have better demonstrated and understood 
the pain dynamics involved. Moreover, with studies with 
a larger sample size more clear conclusions could have 
been derived.
Conclusion
We found that use of single oral dose of Diclofenac and 
Silodosin is very effective in relieving pain after stent 
removal and the combination was not found to be more 
effective than the single agent. Thus, we recommend use 
of oral Diclofenac or Silodosin before stent removal to 
prevent pain after stent removal.
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